Orthofix Medical (NASDAQ:OFIX) Announces Earnings Results

Orthofix Medical (NASDAQ:OFIX) issued its earnings results on Wednesday. The medical device company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02, FiscalAI reports. The company had revenue of $210.93 million during the quarter, compared to the consensus estimate of $209.28 million. Orthofix Medical had a negative return on equity of 14.05% and a negative net margin of 7.41%.

Here are the key takeaways from Orthofix Medical’s conference call:

• Q2 net sales grew 5% on a pro forma constant-currency basis, led by 10% growth in global spine fixation and 11% growth in global limb reconstruction. Biologics stabilized to approximately flat year over year after significant declines in 2025.
• CMS restored Medicare reimbursement for bone-growth stimulators retroactive to May 18, providing an estimated $12 million benefit and improving visibility for Therapeutic Solutions in the second half. The company also launched the redesigned AccelStim 2.0 device.
• Orthofix raised its 2026 outlook to $845 million-$855 million in net sales and $95 million-$98 million in adjusted EBITDA. The increase includes reimbursement recovery and approximately $15 million of European distributor inventory purchases tied to MDR certification work, with most of that revenue expected in Q4.
• Smaller U.S. spine distributors, representing roughly 20% of spine sales, continue to underperform due primarily to weak asset utilization and channel productivity. Management expects the softness to persist through year-end and is considering consolidating or exiting weaker relationships, which implies only about 2%-3% core growth in the second half excluding the European order.
• The company is investing in clinical evidence for biologics products and pursuing a potential diabetic-foot-ulcer indication for its limb-reconstruction technologies. Orthofix also completed initial VIRATA minimally invasive spine cases and expects a full market launch late in the fourth quarter.

Orthofix Medical Stock Performance

Shares of NASDAQ OFIX traded down $0.27 during midday trading on Friday, reaching $10.34. 373,201 shares of the company traded hands, compared to its average volume of 338,624. The company has a market cap of $417.74 million, a price-to-earnings ratio of -6.71 and a beta of 0.68. The stock has a 50-day moving average price of $10.50 and a 200 day moving average price of $11.72. Orthofix Medical has a 52 week low of $8.85 and a 52 week high of $16.99. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 1.76.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on OFIX. Barrington Research boosted their price objective on Orthofix Medical from $15.00 to $17.00 and gave the company an “outperform” rating in a research report on Monday, July 6th. TD Cowen reissued a “hold” rating on shares of Orthofix Medical in a report on Thursday, May 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Orthofix Medical in a research report on Friday, July 17th. Stifel Nicolaus cut their price objective on shares of Orthofix Medical from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 22nd. Finally, Wall Street Zen cut shares of Orthofix Medical from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Orthofix Medical has a consensus rating of “Hold” and an average price target of $16.00.

Insider Transactions at Orthofix Medical

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,670 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.38, for a total transaction of $34,424.60. Following the transaction, the insider owned 66,330 shares of the company’s stock, valued at approximately $622,175.40. This trade represents a 5.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC raised its holdings in Orthofix Medical by 67.7% during the first quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock worth $333,000 after purchasing an additional 8,241 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Orthofix Medical by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after buying an additional 1,213 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Orthofix Medical in the first quarter valued at $1,076,000. Strs Ohio acquired a new stake in shares of Orthofix Medical in the first quarter valued at $150,000. Finally, JPMorgan Chase & Co. boosted its stake in Orthofix Medical by 15.6% during the second quarter. JPMorgan Chase & Co. now owns 193,549 shares of the medical device company’s stock valued at $2,158,000 after buying an additional 26,123 shares in the last quarter. 89.76% of the stock is currently owned by institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.